Navigation Links
Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
Date:1/4/2012

BALTIMORE, Jan. 4, 2012 /PRNewswire/ -- Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022.  ARC-2022 is being developed by Arcion for pain associated with post-herpetic neuralgia (PHN) and shingles.  ARC-2022 has been evaluated in a single-dose Phase 1 pharmacokinetic study in adult patients with PHN.  The results indicated sustained delivery without requirement of a patch or skin-occlusion.  No safety issues were identified.

"With ARC-2022 our goal is to deliver lidocaine to the skin without the requirement of an occlusive patch.  With topical delivery, systemic toxicities and CNS side effects can be avoided and the abnormal pain signals are suppressed at the point of origination in the skin," said James N. Campbell, MD, President and CEO of Arcion.  "Issues with presently available FDA products for the treatment of neuropathic pain include limited efficacy and frequent side effects.  Patches can pose challenges to the patient, particularly when they must be applied over joints, feet, hands, hairy or sweaty skin, or areas such as the face where aesthetics come into play.  We believe ARC-2022 is an excellent candidate to address a significant market need with a product that optimizes delivery directly to the painful skin without the need for a patch." 

"This patent allowance represents the second patent in the last three months for our two topical chronic pain programs, ARC-2022 and ARC-4558.  These products now have patent protection through 2029 and beyond," commented Kerrie Brady, COO of Arcion. "We are on track to advance ARC-4558 for painful diabetic neuropathy into Phase 3 studies and ARC-2022 into further Phase 1/2 studies in 2012. ARC-4558 has received fast-track status with the FDA."


'/>"/>

SOURCE Arcion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
2. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
3. BioNeutral Group Receives $400,000 in Equity Financing
4. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
5. Intimate Bridge 2 Conception, Inc. Receives $4.3M
6. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
7. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
8. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
9. Watsons Generic Yaz(R) Receives FDA Approval
10. UCSB professor receives award for graphene electronics research
11. iBio, Inc. Receives Notice from NYSE Amex Staff that Company Currently is Below Certain Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... This webinar will focus on EMA and FDA ... biosimilars. , Regulatory frameworks are evolving many countries to ... complex nature of biopharmaceuticals makes the demonstration of biosimilarity ... Based on the specific aspects of biosimilar drug development ...
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... , ... ... ... ...
... ... with the upside of not only producing a low sodium meat product but with ... ... manufacturer of value-added ingredients into the natural food, nutraceutical and medical food market, is ...
... ... ... ... ...
Cached Biology Technology:China Medical Technologies Reports Third Fiscal Quarter Financial Results 2China Medical Technologies Reports Third Fiscal Quarter Financial Results 3China Medical Technologies Reports Third Fiscal Quarter Financial Results 4China Medical Technologies Reports Third Fiscal Quarter Financial Results 5China Medical Technologies Reports Third Fiscal Quarter Financial Results 6China Medical Technologies Reports Third Fiscal Quarter Financial Results 7China Medical Technologies Reports Third Fiscal Quarter Financial Results 8China Medical Technologies Reports Third Fiscal Quarter Financial Results 9China Medical Technologies Reports Third Fiscal Quarter Financial Results 10China Medical Technologies Reports Third Fiscal Quarter Financial Results 11China Medical Technologies Reports Third Fiscal Quarter Financial Results 12China Medical Technologies Reports Third Fiscal Quarter Financial Results 13China Medical Technologies Reports Third Fiscal Quarter Financial Results 14China Medical Technologies Reports Third Fiscal Quarter Financial Results 15China Medical Technologies Reports Third Fiscal Quarter Financial Results 16China Medical Technologies Reports Third Fiscal Quarter Financial Results 17China Medical Technologies Reports Third Fiscal Quarter Financial Results 18China Medical Technologies Reports Third Fiscal Quarter Financial Results 19China Medical Technologies Reports Third Fiscal Quarter Financial Results 20China Medical Technologies Reports Third Fiscal Quarter Financial Results 21China Medical Technologies Reports Third Fiscal Quarter Financial Results 22New Study Shows Nu-Tek's Modified Potassium Chloride Improves Yields in Meat Processing 2New Study Shows Nu-Tek's Modified Potassium Chloride Improves Yields in Meat Processing 3Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease 2Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease 3
(Date:4/23/2014)... data shows Africa,s Congo rainforest, the second-largest tropical rainforest ... greenness over the past decade. , The study, led ... of New York, shows between 2000 and 2012 the ... intensified. The research, published Wednesday in Nature , ... explore the effects of long-term drought on the Congo ...
(Date:4/23/2014)... of asthma, allergies and other chronic inflammatory disorders among ... part to their reduced exposure to the microbes that ... paper. , The article, published in the journal ... in urban centers who have less access to green ... a condition caused by immune system dysfunction. , When ...
(Date:4/23/2014)... German . Man ... difference between sexes depends on one single element of the genome: ... two sexual chromosomes are X and Y, whereas women have two ... morphological and physiological differences between males and females. , But this ... the X and Y were identical, until the Y started to ...
Breaking Biology News(10 mins):NASA satellites show drought may take toll on Congo rainforest 2NASA satellites show drought may take toll on Congo rainforest 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3Male or female? 2Male or female? 3
... KNOXVILLE -- Research by a small group of microbiologists ... of the Earth: the realm just beneath the deep ocean ... on our planet. Beth Orcutt, a post-doctoral fellow at ... presented her new findings about this little researched realm today ...
... research studies should not be disclosed to participants without ... of the European Society of Human Genetics today (Monday). ... Policy, Management and Evaluation at the University of Toronto, ... held by many ethicists that individual genetic research findings ...
... Researchers at Rice University, Purdue University and the ... about why some fluids containing polymers -- including saliva ... do not. The findings are published online this ... Study co-author Matteo Pasquali, professor in chemical and biomolecular ...
Cached Biology News:New research into the deep ocean floor yields promising results for microbiologists 2Should the results of individual genetic studies be disclosed to participants? 2Should the results of individual genetic studies be disclosed to participants? 3Answer to saliva mystery has practical impact 2
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
Immunogen: Recombinant full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: Synthetic peptide: R(89) L A F T V D D N P T K P T T R Q R Y(107) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: